期刊
NATURE REVIEWS UROLOGY
卷 16, 期 5, 页码 302-317出版社
NATURE PORTFOLIO
DOI: 10.1038/s41585-019-0178-2
关键词
-
资金
- Australian Government Research Training Program Scholarship
- University of Queensland Graduate School International Travel Award
- National Breast Cancer Foundation of Australia [CG 1207]
- Australian Research Council [DP 140104006, DP 160102836]
- Royal Brisbane Women's Hospital Foundation
- US National Institutes of Health
- US Department of Defense
- Prostate Cancer Foundation
- A. Alfred Taubman Medical Research Institute
The accurate identification and stratified treatment of clinically significant early-stage prostate cancer have been ongoing concerns since the outcomes of large international prostate cancer screening trials were reported. The controversy surrounding clinical and cost benefits of prostate cancer screening has highlighted the lack of strategies for discriminating high-risk disease (that requires early treatment) from low-risk disease (that could be managed using watchful waiting or active surveillance). Advances in molecular subtyping and multiomics nanotechnology-based prostate cancer risk delineation can enable refinement of prostate cancer molecular taxonomy into clinically meaningful and treatable subtypes. Furthermore, the presence of intertumoural and intratumoural heterogeneity in prostate cancer warrants the development of novel nanodiagnostic technologies to identify clinically significant prostate cancer in a rapid, cost-effective and accurate manner. Circulating and urinary next-generation prostate cancer biomarkers for disease molecular subtyping and the newest complementary nanodiagnostic platforms for enhanced biomarker detection are promising tools for precision prostate cancer management. However, challenges in merging both aspects and clinical translation still need to be overcome.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据